



**CANCER**  
**HAS NO BORDERS**  
**NEITHER DO WE**



# The BeiGene Mission

At BeiGene, our mission is to build the first next-generation global biotechnology company – one that expands the highest quality therapies to more people around the world – by addressing the two biggest challenges in fighting cancer today: access to medicines and affordability.

## Our Global Impact:

**10k+** Colleagues in over 40 offices on five continents

**17** approved oncology medicines, including collaborations

**800k+** patients reached worldwide

Yet this is only the beginning of our global journey. That's why we say,

***“Cancer has no borders, neither do we.”***



# Our Commitment to Patients

*As we work to provide treatments to patients worldwide, we also strive to support their families, caregivers, and the advocacy organizations who act on their behalf. Our values and mission drive us to elevate patient voices, engage in the community, and evolve the global health conversation to improve care.*

**Our passion is partnership.**

**Our commitment to patients is resolute.**

## We engage

with cancer communities around the world to gain insights to inform disease education, awareness efforts and patient support programs.

## We advance

health equity by helping patients get the medicines they need through various access and support programs.

## We aspire

to bring the patient voice into research – from clinical trial design to patient-centered outcomes research – to create solutions that are most meaningful to them.

## We support

initiatives and programs that help patients live fuller, more engaged lives.





# A Goal to Deliver First-in-Class & Best-in-Class Therapies

Every day, we strive to discover, develop, and deliver first-in-class and best-in-class therapies that help improve the lives of cancer patients around the world.

*With a portfolio of 17 approved medicines and a broad and deep pipeline focused on hematology and solid tumors, we have the potential to address 80% of the world's cancers by incidence.*

Our world-class research and development engine has:



**One of the largest**  
oncology research teams  
and portfolios



**preclinical programs,**  
the majority with  
first-in-class potential



**molecules** at  
commercial or  
clinical stage



**Phase 3** or potentially  
registration-enabling trials



**This is just the beginning** of what we aim to achieve for patients. Starting in 2024, we anticipate **10 or more** new molecules entering the clinic each year.

# Our Differentiated Approach: Bringing Innovative Medicines to More Patients



Building global cutting-edge internal capabilities:



person global clinical development team



oncology researchers, one of the largest such teams in the industry



member science-based global commercial team



State-of-the-art internal manufacturing capabilities

We conduct our own clinical trials, largely free of clinical research organization, to improve speed, cost, and quality.



**~140 trials**

initiated in 48 countries



**20,000+ patients**

enrolled

## World-class innovation

We have a strong, deep, and innovative clinical portfolio validated by clinical results, global approvals, and major global pharma collaborations.

## Driving faster and broader access to medicines


We collaborate with health systems around the world to accelerate the availability of our treatments for patients.

# Partner of Choice

**Global strategic collaborations to expand access to important oncology medicines for patients around the globe.**

We are committed to partnering with the best minds in academia, biotech, and pharma around the world to bring the highest quality and most innovative therapies to billions more people. We team up with organizations who share our patient-centric vision and unwavering commitment to transformational science.

## *Additional Collaborations*



# Our Global Approach to Access and Affordability

We believe that everyone should have access to innovative, life-changing medicines, regardless of where they live or what resources they have.



We leverage several methods to bring our medicines to more patients globally, including:

- Initiating clinical trials globally for a wide range of therapeutic indications
- Establishing patient access programs to provide treatment to those with no therapeutic alternatives
- Pursuing widespread registration in developed and developing markets simultaneously
- Pricing our medicines at levels that enable access to patients
- Partnering with organizations to ensure access in low- and lower middle-income countries



## The Max Foundation:

In 2023, we launched a partnership with The Max Foundation to advance global health by providing access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia in low- and middle-income countries.

# Our Environmental, Social & Governance Commitment

At BeiGene, we believe that **Change Is The Cure**. Our ambition is to be a leading global citizen, acting with courage, creativity, and discipline to ensure we are meeting the diverse needs of our stakeholders – **from patients and colleagues to investors and communities, as well as the environment.**

We understand that our business work plays an important role in creating a more equitable and sustainable world and we are committed to delivering on that promise.

[Our annual ESG report](#) is developed in reference to the Global Reporting Initiative (GRI) and outlines our progress toward short- and long-term targets in five areas.







# BeiGene

Cancer has no borders. Neither do we.



[BeiGene.com](https://www.BeiGene.com)



[@BeiGeneGlobal](https://twitter.com/BeiGeneGlobal)



[info@BeiGene.com](mailto:info@BeiGene.com)



888-123-4455



[LinkedIn.com/Company/BeiGene/](https://www.linkedin.com/company/BeiGene/)